Prescient reports 50% ORR in Phase Ib of PTX-200 for breast cancer

Prescient Therapeutics Ltd. (ASX:PTX) reported data from 10 evaluable patients with HER2-negative breast cancer in a U.S. Phase Ib trial showing that PTX-200 led to an overall response rate (ORR) of ...